Large fat and skin necroses after deep subcutaneous injections of a slow-release somatostatin analogue in a woman with acromegaly

Immunostimulatory effects on THP-1 cells by peptide or protein pharmaceuticals associated with injection site reactions

“…Injection site reaction (ISR) is one of the most commonlyobserved adverse events (AE) associated with subcutaneous administration of peptide or protein pharmaceuticals (Lalezari et al 2003;Nolden et al 2005;Trottier et al 2005;Burman et al 2010;Clarke 2010;Batycka-Baran et al 2012;Kaiser et al 2012). ISRs are typically characterized by one or more of the following symptoms: erythema, pain, itchiness, and induration at the injection site.…”

Diagnostic approach to subcutaneous nodules in patients with neuroendocrine tumours treated with depot somatostatin analogs: a cross‐sectional study

“…While nodules at the injection site have been reported to be infrequent in patients under treatment with SSAs, subcutaneous nodules were found in up to 52% of computed tomography (CT) scans performed in 56 patients with metastatic midgut carcinoid tumours receiving SSAs . Subcutaneous tissue metastases, although rare in GEP‐NETs, have been described as a late manifestation and an important predictor of death .…”

“…1 Somatostatin analogs (SSAs), mainly octreotide and lanreotide, play a key role in their management. [2][3][4] While nodules at the injection site have been reported to be infrequent in patients under treatment with SSAs, 5 subcutaneous nodules were found in up to 52% of computed # Authors contributed equally to the manuscript. tomography (CT) scans performed in 56 patients with metastatic midgut carcinoid tumours receiving SSAs.…”